Figini M - Search Results

1

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy.

Satta A, Grazia G, Caroli F, Frigerio B, Di Nicola M, Raspagliesi F, Mezzanzanica D, Zaffaroni N, Gianni AM, Anichini A, Figini M. Satta A, et al. Among authors: figini m. Front Immunol. 2019 Oct 25;10:2514. doi: 10.3389/fimmu.2019.02514. eCollection 2019. Front Immunol. 2019. PMID: 31708930 Free PMC article.

2

Approaches to implement bispecific antibody treatment of ovarian carcinoma.

Canevari S, Mezzanzanica D, Mazzoni A, Negri DR, Figini M, Ramakrishna V, Bolis G, Colnaghi MI. Canevari S, et al. Among authors: figini m. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):187-9. doi: 10.1007/s002620050429. Cancer Immunol Immunother. 1997. PMID: 9435870 Free PMC article. Clinical Trial. No abstract available.

3

Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection.

Figini M, Obici L, Mezzanzanica D, Griffiths A, Colnaghi MI, Winter G, Canevari S. Figini M, et al. Cancer Res. 1998 Mar 1;58(5):991-6. Cancer Res. 1998. PMID: 9500461

4

Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.

Mezzanzanica D, Canevari S, Mazzoni A, Figini M, Colnaghi MI, Waks T, Schindler DG, Eshhar Z. Mezzanzanica D, et al. Among authors: figini m. Cancer Gene Ther. 1998 Nov-Dec;5(6):401-7. Cancer Gene Ther. 1998. PMID: 9917095

5

Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2.

Turatti F, Mezzanzanica D, Nardini E, Luison E, Maffioli L, Bambardieri E, de Lalla C, Canevari S, Figini M. Turatti F, et al. Among authors: figini m. Cancer Immunol Immunother. 2001 Feb;49(12):679-86. doi: 10.1007/s002620000162. Cancer Immunol Immunother. 2001. PMID: 11258794 Free PMC article.

6

A step further in understanding the biology of the folate receptor in ovarian carcinoma.

Bagnoli M, Canevari S, Figini M, Mezzanzanica D, Raspagliesi F, Tomassetti A, Miotti S. Bagnoli M, et al. Among authors: figini m. Gynecol Oncol. 2003 Jan;88(1 Pt 2):S140-4. doi: 10.1006/gyno.2002.6705. Gynecol Oncol. 2003. PMID: 12586106 Review. No abstract available.

7

Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies.

Figini M, Ferri R, Mezzanzanica D, Bagnoli M, Luison E, Miotti S, Canevari S. Figini M, et al. Gene Ther. 2003 Jun;10(12):1018-25. doi: 10.1038/sj.gt.3301962. Gene Ther. 2003. PMID: 12776159

8

CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma.

Mezzanzanica D, Balladore E, Turatti F, Luison E, Alberti P, Bagnoli M, Figini M, Mazzoni A, Raspagliesi F, Oggionni M, Pilotti S, Canevari S. Mezzanzanica D, et al. Among authors: figini m. Clin Cancer Res. 2004 Aug 1;10(15):5202-14. doi: 10.1158/1078-0432.CCR-03-0537. Clin Cancer Res. 2004. PMID: 15297424

9

A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and -4 processing.

Gaggero A, De Ambrosis A, Mezzanzanica D, Piazza T, Rubartelli A, Figini M, Canevari S, Ferrini S. Gaggero A, et al. Among authors: figini m. Oncogene. 2004 Sep 30;23(45):7552-60. doi: 10.1038/sj.onc.1208036. Oncogene. 2004. PMID: 15326478

10

Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor.

Turatti F, Figini M, Alberti P, Willemsen RA, Canevari S, Mezzanzanica D. Turatti F, et al. Among authors: figini m. J Gene Med. 2005 Feb;7(2):158-70. doi: 10.1002/jgm.647. J Gene Med. 2005. PMID: 15538730

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

137 results

Search Page